Skip to main content

Product support for your patients.

Novo Nordisk offers services through NovoSecure™, a support program designed to assist your patients throughout the reimbursement process.

Novosecure™ website home page

Insurance coordination.

Magnifying glass of a dollar sign
Magnifying glass of a dollar sign

QuickCheck™

QuickCheck™ offers benefits verification. A NovoSecure™ Specialist assists to verify coverage, and usually within 4 hours, your office will receive the Summary of Benefits.a  

aAvailable from 9:00 am to 4:00 pm ET.


Folder with two pages icon
Folder with two pages icon

Prior Authorizations

NovoSecure™ helps determine whether insurance providers require prior authorizations and what patients will need to submit one.

Appeals

If initial insurance claims are denied, NovoSecure™ can assist physicians and eligible patients through the appeal process.b  

bAppeal support is available only for commercially insured patients with an FDA-approved Novo Nordisk product indication. Patients who participate in any government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible for appeal support.

To obtain a QuickCheck™ form, or for help with insurance coordination, contact a NovoSecure™ Specialist by calling 1-844-NOVO-SEC (1-844-668-6732) or by emailing mynovosecurespecialist@mynovosecure.com.

Product support.


cEnrolled patients pay $0 per fill for up to 12 months from the date of Savings Card activation, subject to a maximum savings of $12,000 per calendar year. In order to redeem this offer patient must have a valid prescription for the brand being filled. A valid Prescriber ID# is required on the prescription. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. The brand and the prescription being filled must be covered by the patient’s commercial insurance plan. Offer excludes full cash-paying patients. This offer may not be redeemed for cash.  By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described herein and will not seek reimbursement for any benefit received through this card. Novo Nordisk’s Eligibility and Restrictions, and Offer Details may change from time to time. Re-confirmation of information may be requested periodically to ensure accuracy of data and compliance with terms.

This offer is valid in the United States and may be redeemed at participating retail pharmacies. Absent a change in Massachusetts law, effective July 1, 2019, the Savings Card will no longer be valid for residents of Massachusetts. Void where taxed, restricted, or prohibited by law. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Cash Discount Cards and other non-insurance plans are not valid as primary insurance under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. This Savings Card cannot be combined with any coupon, certificate, voucher, or similar offer.  Patient is responsible for complying with any insurance carrier co-payment disclosure requirements, including disclosing any savings received from this program. It is illegal to (or offer to) sell, purchase, or trade this offer.  This program is managed by ConnectiveRx on behalf of Novo Nordisk. The parties reserve the right to rescind, revoke or amend this offer without notice at any time.

dThe Novo Nordisk Hemophilia & Rare Bleeding Disorders Product Assistance Program (PAP) is administered by NovoSecure™. To qualify for the PAP, patients must demonstrate financial need and be prescribed a Novo Nordisk factor product for an FDA indicated condition. Several factors are considered in evaluating financial need, including cost of living, size of household, and burden of total medical expenses. If the applicant qualifies under the PAP guidelines, a limited supply of the requested medication(s) will be shipped to the patient. Patients who qualify for PAP may be eligible to receive the prescribed Novo Nordisk product, for up to 1 year from the approval date. Product limits vary.
ePatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.

two hands holding a green plus sign icon

Interim Product Program

This limited program provides hemophilia therapy to eligible patients during a coverage gap. Contact a NovoSecure™ Specialist by calling 1-844-NOVOSEC (1-844-668-6732).e

Young lady on a headset
Young lady on a headset

Contact a NovoSecure™ Specialist.

When therapy begins, NovoSecure™ assigns a NovoSecure™ Specialist to assist with reimbursement support, including benefits investigations and insurance coordination.

Call 1-844-NOVO-SEC (1-844-668-6732) to speak with a NovoSecure™ Specialist.

Get to know NovoSecure™.

Novosecure™ website home page

Novo Nordisk offers services through NovoSecure™, a support program designed to assist patients throughout the reimbursement process.

Selected Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Prescribing Information.